Sanjay S. Shukla
2022
In 2022, Sanjay S. Shukla earned a total compensation of $2.4M as President and CEO at aTYR PHARMA, a 27% increase compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $224,500 |
---|---|
Option Awards | $1,386,876 |
Salary | $561,243 |
Stock Awards | $229,080 |
Other | $9,736 |
Total | $2,411,435 |
Shukla received $1.4M in option awards, accounting for 58% of the total pay in 2022.
Shukla also received $224.5K in non-equity incentive plan, $561.2K in salary, $229.1K in stock awards and $9.7K in other compensation.
Rankings
In 2022, Sanjay S. Shukla's compensation ranked 1,506th out of 5,760 executives tracked by ExecPay. In other words, Shukla earned more than 73.9% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 1,506 out of 5,760 | 74th |
Division Manufacturing | 756 out of 3,136 | 76th |
Major group Chemicals And Allied Products | 295 out of 1,422 | 79th |
Industry group Drugs | 274 out of 1,323 | 79th |
Industry Biological Products, Except Diagnostic Substances | 69 out of 291 | 76th |
Source: SEC filing on April 5, 2024.
Shukla's colleagues
We found two more compensation records of executives who worked with Sanjay S. Shukla at aTYR PHARMA in 2022.
News
aTYR PHARMA CEO Sanjay Shukla's 2023 pay falls 46% to $1.3M
April 5, 2024
aTYR PHARMA CEO Sanjay Shukla's 2021 pay jumps 75% to $1.9M
March 22, 2022
aTYR PHARMA CEO Sanjay Shukla's 2020 pay jumps 63% to $1.1M
March 23, 2021
aTYR PHARMA CEO Sanjay Shukla's 2019 pay falls 52% to $664K
April 2, 2020
aTYR PHARMA CEO Sanjay Shukla's 2018 pay falls 36% to $1.4M
March 28, 2019